501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Provides
Update on
Marijuana Breathalyzer Development
The Cannabix Marijuana Breathalyzer
system
is being developed to give law enforcement and employers a tool to
enforce public safety.
Vancouver, British
Columbia -- March
14,
2019
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the
Cannabix Marijuana Breathalyzer for law enforcement and the
workplace, is pleased to
report
that early testing with
its breath collection
unit ("BCU") has
thus
far provided
stable and
consistent results.
In late January, the Company received an initial
version of its
portable handheld
device for the
collection of
breath samples at the point of care.
Testing
with human subjects using the
BCU,
has
improved consistency of breath sample collection,
and
has
provided
important real-time
data
parameters
on
breath
flow rate, volume, relative
humidity,
carbon dioxide
levels, and temperature.
Engineers
may
make additional
adjustments to the BCU based on this early
testing of the unit and additional
units are planned to be built for field testing
purposes.
The
Company also reports recent characterization work with the
Cannabix's FAIMS (field asymmetric
waveform ion mobility spectrometry) THC
detection device
has shown the ability to supress a
range
of ions
(both
low mass and high mass) from the spectrum
allowing for THC (9-tetrahydrocannabinol)
detection from both
human breath and standards. In particular, scientists
are
working quickly to finalize
specific FAIMS
geometries that will
allow
for optimal ion filtering capability. FAIMS works as an
"ion blocking" technology, essentially blocking unwanted
ions/analytes and allowing specified ions (like
THC)
to pass
through for detection.
In
addition to THC, Cannabix scientists are using FAIMS to
detect two key metabolites
of THC,
being 11-hydroxy-delta-9-tetrahydrocannabinol and
11-nor-9-carboxy-tetrahydrocannabinol in standards
and in
breath.
Marijuana contains
several cannabinoids in addition to THC,
several of which are metabolized in
the body relatively quickly and
have
shorter half-lives. THC can be detectable in blood for
weeks;
whereas,
metabolites such as
11-hydroxy-delta-9-tetrahydrocannabinol and
11-nor-9-carboxy-tetrahydrocannabinol are only detectable
for a
few hours after consumption of cannabis. The detection of THC and
its metabolites in human breath provides for real-time
pharmacokinetic analysis. Such analysis provides a method for the
identification of "recency of use" that will be
important for determining impairment at the
roadside. Detection
capability of the metabolites
provides
analysis of
frequent users of marijuana who tend to retain THC in their body
for longer periods of time, relative to infrequent marijuana users
who tend to clear THC from their body more quickly. This data and
analysis will be important for an eventual court approved
device.
Furthermore,
11-nor-9- carboxy-tetrahydrocannabinol is the primary metabolite
from the liver, which is prevalent from the consumption of
edibles.
Additional
improvements and IP
Engineers have
improved on the design of
the
ionization source
for the instrument which now allows
for
greater voltage control and precision, leading to
greater signal and sensitivity. Furthermore,
improvements have been made to the instrument's heat control
module. The
Company's patent portfolio includes an
exclusive worldwide
license of University of Florida ("UF")
US
Patent 8,237,118 in the area of breath analysis of controlled
substances. Additionally, the
Company has licensed patent
pending
technology from
UF
(PCT/CA2017/000042),
and has
made its own patent
applications since
2015.
The
Company's
technology has
significantly progressed since its original
filings and
new
intellectual
property and trade secrets have been developed that
will
ultimately supersede earlier broad patent applications.
Additional
patent
applications will be filed in due course.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects previous
usage
from
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.